PEPGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 2.85K shares.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 14.89K shares, a 146.66% increase year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 6.04K shares.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 24.89K shares, a 88.14% decline from fiscal 2024.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 209.88K shares, a 109.15% increase from fiscal 2023.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 100.35K shares, a 23.48% increase from fiscal 2022.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 81.27K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | 2.85K shares 10-Q · filed 2026-05-12 | |
| 2025-12-31 | 14.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | 24.89K shares 10-K · filed 2026-03-04 |
| 2024-12-31 | 6.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | 209.88K shares 10-K · filed 2025-02-24 |
| 2024-09-30 | 39.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2024-06-30 | 128.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2024-03-31 | 36.20K shares 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 100.35K shares 10-K/A · filed 2024-03-29 | |
| 2022-12-31 | 81.27K shares 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |